Your session is about to expire
← Back to Search
Protein Concentrate
APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee
Phase 1 & 2
Waitlist Available
Research Sponsored by Cytonics Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 week
Summary
This trial uses a device to concentrate a substance from a patient's blood and inject it into their painful knee. The substance helps stop harmful elements from breaking down knee tissue, aiming to reduce pain and slow joint damage. A new blood-based treatment has been developed to concentrate helpful components and reduce inflammation, with promising early results in terms of safety and improvement.
Eligible Conditions
- Osteoarthritis
- Pain
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 week
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 week
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Reduction in pain after 8 weeks
Reduction in pain while walking at 8 weeks
Secondary study objectives
Reduction in pain after 2 weeks
Reduction in pain at 24 weeks
Reduction in pain while walking after 24 weeks
+1 moreTrial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: APIC-CF, 2ccExperimental Treatment1 Intervention
APIC-CF, 2cc, one at first day
Group II: APIC-CF 4cc,Experimental Treatment1 Intervention
APIC-CF 4cc, once at first day
Group III: SalinePlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Cytonics CorporationLead Sponsor
3 Previous Clinical Trials
322 Total Patients Enrolled
1 Trials studying Osteoarthritis
22 Patients Enrolled for Osteoarthritis